Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   MEDICAL JOURNAL OF THE ISLAMIC REPUBLIC OF IRAN (MJIRI)   2017 , Volume 31 , Number 1; Page(s) 0 To 0.
 
Paper: 

Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis

 
DOI: 

10.14196/mjiri.31.88

 
Author(s):  DAVARI MAJID, AMANI BAHMAN, MOKARIAN FARIBORZ, HOSEINI MOHSEN, AKBARZADEH ARASH, Heidarzadeh Khoramabadi Nastaran*
 
* Department of Drug and Food Control, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
 
Abstract: 
Background: Trastuzumab in combination with chemotherapy has long been established as a standard treatment for HER2-positive patients in early stage breast cancer (BC). The present study aimed at assessing the effectiveness of trastuzumab adjuvant therapy in early stage BC in overall survival (OS) and disease-free survival (DFS). Methods: A systematic review and meta-analysis was performed to evaluate the effectiveness of trastuzumab adjuvant therapy. Pub-Med, Cochrane library, Scopus, Web of Science, and Embase databases were searched for relevant RCTs from the beginning to February 2017. Quality assessment of studies was conducted using the Cochrane Risk of Bias Tool. The desired outcomes were OS and DFS. Results: A total of 1818 articles were identified first, however, only 11 studies were eligible to be included in this study. Our findings and meta-analysis results revealed that trastuzumab is effective in increasing OS (OS hazard ratio:-0. 286 ± 0. 049, 95%CI (-0. 381,-0. 191)) and improving DFS (DFS hazard ratio:-0. 419± 0. 077, 95%CI (-0. 569,-0. 269)). The most serious but negligible side effect of trastuzumab is congestive heart failure. Conclusion: Adding trastuzumab as adjuvant therapy in early stages of BC in HER2 positive patients could increase OS and DFS of the patients effectively.
 
Keyword(s): Trastuzumab,Breast Cancer,Herceptin,Meta-analysis,Adjuvant Therapy
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

DAVARI, M., & AMANI, B., & MOKARIAN, F., & HOSEINI, M., & AKBARZADEH, A., & Heidarzadeh Khoramabadi, N. (2017). Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis. MEDICAL JOURNAL OF THE ISLAMIC REPUBLIC OF IRAN (MJIRI), 31(1), 0-0. https://www.sid.ir/en/journal/ViewPaper.aspx?id=665906



Vancouver: Copy

DAVARI MAJID, AMANI BAHMAN, MOKARIAN FARIBORZ, HOSEINI MOHSEN, AKBARZADEH ARASH, Heidarzadeh Khoramabadi Nastaran. Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis. MEDICAL JOURNAL OF THE ISLAMIC REPUBLIC OF IRAN (MJIRI). 2017 [cited 2021July27];31(1):0-0. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=665906



IEEE: Copy

DAVARI, M., AMANI, B., MOKARIAN, F., HOSEINI, M., AKBARZADEH, A., Heidarzadeh Khoramabadi, N., 2017. Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis. MEDICAL JOURNAL OF THE ISLAMIC REPUBLIC OF IRAN (MJIRI), [online] 31(1), pp.0-0. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=665906.



 
  pdf-File
Yearly Visit 21
 
 
Latest on Blog
Enter SID Blog